Predictive biomarkers for immunotherapy in gastric cancer

Abstract

Gastric cancer remains a significant global health burden, and while immunotherapy offers promising therapeutic avenues, its efficacy varies greatly among patients. The key challenge is accurately identifying treatment responders, while alternative strategies are necessary for non-responders. Biomarkers such as PD-L1 expression, tumor mutational burden, mismatch repair status, and Epstein-Barr virus infection have shown predictive potential, yet the quest for more reliable markers continues to be challenging. Emerging technologies, including liquid biopsy, single-cell sequencing, and artificial intelligence, present novel approaches to enhancing individualized research and improving predictive capabilities. This review provides a comprehensive analysis of current biomarkers and introduces emerging candidates from recent studies, thereby contributing to the ongoing efforts to refine patient stratification and treatment strategies.

Keywords

Gastric Cancer / immunotherapy / immune checkpoint inhibitor / predictive biomarker

References

[1] Sung H,Siegel RL.Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J Clin2021;71:209-49

[2] Wagner AD,Moehler M.Chemotherapy for advanced gastric cancer.Cochrane Database Syst Rev2017;8:CD004064 PMCID:PMC6483552

[3] Xie J,Jin L.Immunotherapy of gastric cancer: past, future perspective and challenges.Pathol Res Pract2021;218:153322

[4] Yu X,Wu J.Evolving perspectives regarding the role of the PD-1/PD-L1 pathway in gastric cancer immunotherapy.Biochim Biophys Acta Mol Basis Dis2024;1870:166881

[5] Fuchs CS,Jang RW.Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial.JAMA Oncol2018;4:e180013

[6] Lei M,Pandya D.Analyses of PD-L1 and inflammatory gene expression association with efficacy of nivolumab ± ipilimumab in gastric cancer/gastroesophageal junction cancer.Clin Cancer Res2021;27:3926-35

[7] Xu J,Pan Y.Sintilimab plus chemotherapy for unresectable gastric or gastroesophageal junction cancer: the ORIENT-16 randomized clinical trial.JAMA2023;330:2064-74 PMCID:PMC10698618

[8] Janjigian YY,Moehler M.First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial.Lancet2021;398:27-40 PMCID:PMC8436782

[9] Wainberg ZA,Tabernero T.Efficacy of pembrolizumab (pembro) monotherapy versus chemotherapy for PD-L1-positive (CPS ≥10) advanced G/GEJ cancer in the phase II KEYNOTE-059 (cohort 1) and phase III KEYNOTE-061 and KEYNOTE-062 studies.J Clin Oncol2020;38:4

[10] Muro K,Shankaran V.Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial.Lancet Oncol2016;17:717-26

[11] Janjigian YY,Calvo E.CheckMate-032 study: efficacy and safety of nivolumab and nivolumab plus ipilimumab in patients with metastatic esophagogastric cancer.J Clin Oncol2018;36:2836-44 PMCID:PMC6161834

[12] Chen LT,Ryu MH.A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data.Gastric Cancer2020;23:510-9 PMCID:PMC7165140

[13] Bang YJ,Van Cutsem E.Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300.Ann Oncol2018;29:2052-60 PMCID:PMC6225815

[14] Shitara K,Bang YJ.Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial.Lancet2018;392:123-33

[15] Xu J,Pan Y.LBA53 Sintilimab plus chemotherapy (chemo) versus chemo as first-line treatment for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (ORIENT-16): First results of a randomized, double-blind, phase III study.Ann Oncol2021;32:S1331

[16] Burtness B,Greil R.Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.Lancet2019;394:1915-28

[17] Kang YK,Ryu MH.Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial.Lancet Oncol2022;23:234-47

[18] Yamaguchi K,Sakai D.Phase IIb study of pembrolizumab combined with S-1 + oxaliplatin or S-1 + cisplatin as first-line chemotherapy for gastric cancer.Cancer Sci2022;113:2814-27

[19] Rha SY,Yañez P.Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial.Lancet Oncol2023;24:1181-95

[20] Janjigian YY,Bai Y.Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial.Lancet2023;402:2197-208

[21] Li S,Xie F.Neoadjuvant therapy with immune checkpoint blockade, antiangiogenesis, and chemotherapy for locally advanced gastric cancer.Nat Commun2023;14:8 PMCID:PMC9810618

[22] Tang Z,Liu D.The neo-PLANET phase II trial of neoadjuvant camrelizumab plus concurrent chemoradiotherapy in locally advanced adenocarcinoma of stomach or gastroesophageal junction.Nat Commun2022;13:6807 PMCID:PMC9649722

[23] Kelly RJ,Zaidi AH.Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal/gastroesophageal junction cancer: a phase Ib trial and ctDNA analyses.Nat Med2024;30:1023-34 PMCID:PMC11031406

[24] Reck M,Robinson AG.Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score ≥ 50.J Clin Oncol2021;39:2339-49 PMCID:PMC8280089

[25] Boll LM,Camarena ME.Predicting immunotherapy response of advanced bladder cancer through a meta-analysis of six independent cohorts.Nat Commun2025;16:1213 PMCID:PMC11842772

[26] Balar AV,Rosenberg JE.Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.Lancet2017;389:67-76 PMCID:PMC5568632

[27] Powles T,van der Heijden MS.Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial.Lancet2018;391:748-57

[28] Marabelle A,Lopez J.Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study.Lancet Oncol2020;21:1353-65

[29] Joshi SS.Current treatment and recent progress in gastric cancer.CA Cancer J Clin2021;71:264-79 PMCID:PMC9927927

[30] Wu Y,Du C.The predictive value of tumor mutation burden on efficacy of immune checkpoint inhibitors in cancers: a systematic review and meta-analysis.Front Oncol2019;9:1161 PMCID:PMC6848266

[31] Xiang K,Yang B.TM-score predicts immunotherapy efficacy and improves the performance of the machine learning prognostic model in gastric cancer.Int Immunopharmacol2024;134:112224

[32] Wang F,Wang FH.Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432.Ann Oncol2019;30:1479-86 PMCID:PMC6771223

[33] Mishima S,Nakamura Y.Clinicopathological and molecular features of responders to nivolumab for patients with advanced gastric cancer.J Immunother Cancer2019;7:24 PMCID:PMC6357506

[34] Schumacher TN.Neoantigens in cancer immunotherapy.Science2015;348:69-74

[35] Zeng D,Zhou R.Tumor microenvironment characterization in gastric cancer identifies prognostic and immunotherapeutically relevant gene signatures.Cancer Immunol Res2019;7:737-50

[36] Kim ST,Bass AJ.Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer.Nat Med2018;24:1449-58

[37] Sun YT,Zhao Q.PD-1 antibody camrelizumab for Epstein-Barr virus-positive metastatic gastric cancer: a single-arm, open-label, phase 2 trial.Am J Cancer Res2021;11:5006-15 PMCID:PMC8569350

[38] Qiu MZ,Wu Z.Dynamic single-cell mapping unveils Epstein-Barr virus-imprinted T-cell exhaustion and on-treatment response.Signal Transduct Target Ther2023;8:370 PMCID:PMC10514267

[39] El Helali A,Wong CHL.A meta-analysis with systematic review: efficacy and safety of immune checkpoint inhibitors in patients with advanced gastric cancer.Front Oncol2022;12:908026 PMCID:PMC9660259

[40] Pietrantonio F,Di Bartolomeo M.Predictive role of microsatellite instability for PD-1 blockade in patients with advanced gastric cancer: a meta-analysis of randomized clinical trials.ESMO Open2021;6:100036 PMCID:PMC7815473

[41] Ooki A,Yoshino K.Potent therapeutic strategy in gastric cancer with microsatellite instability-high and/or deficient mismatch repair.Gastric Cancer2024;27:907-31

[42] André T,Piessen G.Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in localized deficient mismatch repair/microsatellite instability-high gastric or esophagogastric junction adenocarcinoma: the GERCOR NEONIPIGA phase II study.J Clin Oncol2023;41:255-65 PMCID:PMC9839243

[43] Pietrantonio F,Lonardi S.INFINITY: a multicentre, single-arm, multi-cohort, phase II trial of tremelimumab and durvalumab as neoadjuvant treatment of patients with microsatellite instability-high (MSI) resectable gastric or gastroesophageal junction adenocarcinoma (GAC/GEJAC).JCO2023;41:358-358

[44] Nikanjam M,Kurzrock R.Liquid biopsy: current technology and clinical applications.J Hematol Oncol2022;15:131 PMCID:PMC9465933

[45] Ma S,Xu Y.Clinical application and detection techniques of liquid biopsy in gastric cancer.Mol Cancer2023;22:7 PMCID:PMC9832643

[46] Maron SB,Lomnicki S.Circulating tumor DNA sequencing analysis of gastroesophageal adenocarcinoma.Clin Cancer Res2019;25:7098-112 PMCID:PMC6891164

[47] Jin Y,Wang F.The predicting role of circulating tumor DNA landscape in gastric cancer patients treated with immune checkpoint inhibitors.Mol Cancer2020;19:154 PMCID:PMC7596978

[48] Meng Q,Ruan DY.DNA methylation regulator-mediated modification patterns and tumor microenvironment characterization in gastric cancer.Mol Ther Nucleic Acids2021;24:695-710 PMCID:PMC8099484

[49] Zhang M,Wang Z.Molecular characterization of ctDNA from Chinese patients with advanced gastric adenocarcinoma reveals actionable alterations for targeted and immune therapy.J Mol Med2021;99:1311-21

[50] Kawazoe A,Boku N,Terashima M.Current status of immunotherapy for advanced gastric cancer.Jpn J Clin Oncol2021;51:20-7

[51] Xu Z,Gong Z.Exosome-based immunotherapy: a promising approach for cancer treatment.Mol Cancer2020;19:160 PMCID:PMC7661275

[52] Li Z,Long G.Exosomal miRNA-16-5p derived from M1 macrophages enhances T cell-dependent immune response by regulating PD-L1 in gastric cancer.Front Cell Dev Biol2020;8:572689 PMCID:PMC7734296

[53] Jiang Y,Chen G.Nicotinamide metabolism face-off between macrophages and fibroblasts manipulates the microenvironment in gastric cancer.Cell Metab2024;36:1806-22.e11

[54] Tian T,Erel-Akbaba G.Immune checkpoint inhibition in GBM primed with radiation by engineered extracellular vesicles.ACS Nano2022;16:1940-53 PMCID:PMC9020451

[55] Zuo B,Lu Z.Alarmin-painted exosomes elicit persistent antitumor immunity in large established tumors in mice.Nat Commun2020;11:1790 PMCID:PMC7156382

[56] Li TT,Yu J,Zhao LY.Prognostic and predictive blood biomarkers in gastric cancer and the potential application of circulating tumor cells.World J Gastroenterol2018;24:2236-46 PMCID:PMC5989238

[57] Garajová I,Wang H.The role of the microbiome in drug resistance in gastrointestinal cancers.Expert Rev Anticancer Ther2021;21:165-76

[58] Che H,Ma J.Association of Helicobacter pylori infection with survival outcomes in advanced gastric cancer patients treated with immune checkpoint inhibitors.BMC Cancer2022;22:904 PMCID:PMC9389789

[59] Han Z,Dai D.The gut microbiome affects response of treatments in HER2-negative advanced gastric cancer.Clin Transl Med2023;13:e1312 PMCID:PMC10307992

[60] Griffin ME,Becker JL.Enterococcus peptidoglycan remodeling promotes checkpoint inhibitor cancer immunotherapy.Science2021;373:1040-6 PMCID:PMC9503018

[61] Sivan A,Hubert N.Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy.Science2015;350:1084-9 PMCID:PMC4873287

[62] Lee SY,Woo JS.Gut microbiome-derived butyrate inhibits the immunosuppressive factors PD-L1 and IL-10 in tumor-associated macrophages in gastric cancer.Gut Microbes2024;16:2300846 PMCID:PMC10793689

[63] Coutzac C,Paci A.Systemic short chain fatty acids limit antitumor effect of CTLA-4 blockade in hosts with cancer.Nat Commun2020;11:2168 PMCID:PMC7195489

[64] Yang Y,Jin W.Microbiota and metabolites alterations in proximal and distal gastric cancer patients.J Transl Med2022;20:439 PMCID:PMC9524040

[65] Cheng S,Dai D.Multi-omics of the gut microbial ecosystem in patients with microsatellite-instability-high gastrointestinal cancer resistant to immunotherapy.Cell Rep Med2024;5:101355 PMCID:PMC10829783

[66] Karkhah A,Rostamtabar M.Helicobacter pylori evasion strategies of the host innate and adaptive immune responses to survive and develop gastrointestinal diseases.Microbiol Res2019;218:49-57

[67] Magahis PT,Cowzer D.Impact of Helicobacter pylori infection status on outcomes among patients with advanced gastric cancer treated with immune checkpoint inhibitors.J Immunother Cancer2023;11:e007699 PMCID:PMC10619027

[68] Jia K,Xie Y.Helicobacter pylori and immunotherapy for gastrointestinal cancer.Innovation2024;5:100561 PMCID:PMC10878118

[69] Holokai L,Broda T.Increased programmed death-ligand 1 is an early epithelial cell response to helicobacter pylori infection.PLoS Pathog2019;15:e1007468 PMCID:PMC6380601

[70] Heimesaat MM,Plickert R.Helicobacter pylori induced gastric immunopathology is associated with distinct microbiota changes in the large intestines of long-term infected Mongolian gerbils.PLoS One2014;9:e100362 PMCID:PMC4062524

[71] Liu L.The potential of the gut microbiome to reshape the cancer therapy paradigm: a review.JAMA Oncol2022;8:1059-67

[72] Huang W,Xiong W.Noninvasive imaging of the tumor immune microenvironment correlates with response to immunotherapy in gastric cancer.Nat Commun2022;13:5095 PMCID:PMC9427761

[73] He H,Fu H.Imaging diagnosis and efficacy monitoring by [⁸⁹Zr]Zr-DFO-KN035 immunoPET in patients with PD-L1-positive solid malignancies.Theranostics2024;14:392-405 PMCID:PMC10750192

[74] Rong X,Liu Y.PET/CT imaging of activated cancer-associated fibroblasts predict response to PD-1 blockade in gastric cancer patients.Front Oncol2021;11:802257 PMCID:PMC8825781

[75] Jiang Y,Sun Z.Non-invasive tumor microenvironment evaluation and treatment response prediction in gastric cancer using deep learning radiomics.Cell Rep Med2023;4:101146 PMCID:PMC10439253

[76] Huynh E,Guthier C.Artificial intelligence in radiation oncology.Nat Rev Clin Oncol2020;17:771-81

[77] Brahmer JR,Schneider BJ.Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline.J Clin Oncol2018;36:1714-68

[78] Postow MA,Hellmann MD.Immune-related adverse events associated with immune checkpoint blockade.N Engl J Med2018;378:158-68

[79] Masuda K,Nagashima K.Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab.BMC Cancer2019;19:974 PMCID:PMC6805586

[80] Zhang X,Wang J.Are anti-PD-1-associated immune related adverse events a harbinger of favorable clinical prognosis in patients with gastric cancer?.BMC Cancer2022;22:1136 PMCID:PMC9636611

[81] Zhou X,Yang H,Zhang X.Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis.BMC Med2020;18:87 PMCID:PMC7169020

[82] Hu G,Yang L,Yang L.ARID1A deficiency and immune checkpoint blockade therapy: from mechanisms to clinical application.Cancer Lett2020;473:148-55

[83] Chen Q,Hu S.NF-κB-related metabolic gene signature predicts the prognosis and immunotherapy response in gastric cancer.Biomed Res Int2022;2022:5092505 PMCID:PMC8753254

[84] Tong M,He W.Predictive biomarkers for tumor immune checkpoint blockade.Cancer Manag Res2018;10:4501-7

[85] Zeng D,Luo H.Tumor microenvironment evaluation promotes precise checkpoint immunotherapy of advanced gastric cancer.J Immunother Cancer2021;9:e002467 PMCID:PMC8356190

[86] Mori T,Suzuki S.Tertiary lymphoid structures show infiltration of effective tumor-resident T cells in gastric cancer.Cancer Sci2021;112:1746-57

[87] Jiang Q,Wu H.Tertiary lymphoid structure patterns predicted anti-PD1 therapeutic responses in gastric cancer.Chin J Cancer Res2022;34:365-82 PMCID:PMC9468020

[88] Chen Y,Sun Y.Predicting response to immunotherapy in gastric cancer via multi-dimensional analyses of the tumour immune microenvironment.Nat Commun2022;13:4851 PMCID:PMC9388563

[89] Hu X,Wang Q.Molecular classification reveals the diverse genetic and prognostic features of gastric cancer: A multi-omics consensus ensemble clustering.Biomed Pharmacother2021;144:112222

[90] Shi J,Wu X.Characterization of glycometabolism and tumor immune microenvironment for predicting clinical outcomes in gastric cancer.iScience2023;26:106214 PMCID:PMC10006618

[91] Yoo SK,Valero C,Chan TA.Outcomes among patients with or without obesity and with cancer following treatment with immune checkpoint blockade.JAMA Netw Open2022;5:e220448 PMCID:PMC8886536

[92] Namikawa T,Tanioka N.Systemic inflammatory response and nutritional biomarkers as predictors of nivolumab efficacy for gastric cancer.Surg Today2020;50:1486-95

[93] Chen Y,Peng Z.Association of lymphocyte-to-monocyte ratio with survival in advanced gastric cancer patients treated with immune checkpoint inhibitor.Front Oncol2021;11:589022 PMCID:PMC8203902

[94] Qu Z,Wang H.The effect of inflammatory markers on the survival of advanced gastric cancer patients who underwent anti-programmed death 1 therapy.Front Oncol2022;12:783197 PMCID:PMC8845037